Wednesday, Jun 18

Category: CCSVI

New Study Published in Acta Phlebologica

Michael Arata MD of Synergy Health Concepts published the results of a new study into the safety and effectiveness of the TVAM procedure in patients with autonomic dysfunction, including patients with multiple sclerosis and other chronic conditions. The study was published in the April 2014 edition of Acta Phlebologica: A

Dr. Arata Presents Results of New Study at ISET

The results of Synergy’s new study were released today at the International Symposium on Endovascular Therapy (ISET). The study, which can be found here, investigates whether balloon angioplasty induces alterations in the hypothalamus pituitary adrenal (HPA) axis as indicated by changes in levels of ACTH and Cortisol. 88 patients in

Studies Investigate Relationship Between New Treatment and Reduction in Dysautonomia Symptoms in MS Patients

Synergy Health has published a new study, the first in a series, investigating the relationship between treatment for CCSVI (and its successor treatment, TVAM therapy) and the improvement of the symptoms of dysautonomia among M.S. Patients and other groups suffering from autonomic dysfunction. Read our latest study here: While

The Current Status of CCSVI Treatment

Since the condition known as chronic cerebrospinal venous insufficiency (CCSVI) was first described by Dr. Paolo Zamboni in 2008, the relationship between this condition and MS has been investigated and rigorously debated. Yet while Zamboni’s original study saw an over 90% correlation between MS and CCSVI, later studies have cast

Solving the CCSVI Puzzle

CCSVI, as described by Zamboni, is a disturbance of the central nervous system (CNS) venous drainage. The impaired venous drainage seen with CCSVI was postulated to have an effect on multiple sclerosis. Based on the theory of CCSVI, treatment of jugular venous insufficiency has been studied as a potential therapeutic


CCSVI is one of the most controversial topics in modern medical history. CCSVI is held in particular disdain within the neurologic community. University of Buffalo researchers issued a press release regarding their study of CCSVI on March 15th, which was followed shortly by the annual meeting of the American Academy

Deaths Associated with CCSVI Treatment

The everyday practice of medicine involves constant judgmental decisions by physicians in the conscious institution of procedures, tests and observations recognized as effective in treating the patient. Medical treatment in any form is accompanied by risk. Determination of the best treatment option involves weighing the potential benefits of the treatment

CCSVI as Epiphenomenon

The journal Radiology is the premier publication for Radiologists world wide. “Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity” is published in the October 2012 issue of Radiology ( Marziali et al conclude that patients meeting diagnostic

Autonomic Dysfunction Provides All the Answers

CCSVI first burst on the scene in November 2009 following a story by CTV W5, creating enthusiasm among sufferers from debilitating disorders such as Multiple Sclerosis (MS). Initial reports of positive results following treatment of CCSVI were somehow misunderstood by many, particularly via social media, to constitute a “miracle cure”

Make Your First CCSVI Procedure Your Only One

Patients seeking the CCSVI procedure are generally very well informed and have done considerable research before booking their appointment. More often than not, travel to the medical facility is necessary, requiring time away from work and family as well as planning and logistics. The hope for patients is that the